FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:751-756 September 21, 1995 Number 12 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The rates of progression of human immunodeficiency virus (HIV) infection and survival have been reported to differ among sociodemographic groups. It is unclear whether these differences reflect biologic differences or differences in access to medical care.

Methods We measured disease progression and survival in a cohort of 1372 patients seropositive for HIV who were treated at a single urban center (median follow-up, 1.6 years). We calculated the rates of survival for the entire cohort and the rates of progression to the acquired immunodeficiency syndrome (AIDS) or death among the 740 patients who presented without AIDS. We used Cox proportional-hazards analysis to examine factors associated with progression to AIDS and death.

Results Progression to AIDS or death was associated with a CD4 cell count of 201 to 350 per cubic millimeter (relative risk, 2.0; P<0.001), the presence of symptoms at base line (relative risk, 2.0; P<0.001), prior antiretroviral therapy (relative risk, 1.7; P = 0.003), and older age (relative risk per year of age, 1.02; P = 0.03). However, there was no relation between disease progression and sex, race, injection-drug use, income, level of education, or insurance status. In the entire cohort, a lower CD4 cell count, a diagnosis of AIDS, older age, and the receipt of antiretroviral therapy before enrollment were associated with an increased risk of death, whereas the use of prophylaxis against pneumocystis pneumonia, zidovudine use after enrollment, and having a job at base line were associated with lower risks of death. There was no significant difference in survival between men and women, blacks and whites, injection-drug users and those who did not use drugs, or patients whose median annual incomes were $5,000 or less and those whose incomes were more than $5,000.

Conclusions Among patients with HIV infection who received medical care from a single urban center, there were no differences in disease progression or survival associated with sex, race, injection-drug use, or socioeconomic status. Differences found in other studies may reflect differences in the use of medical care.

Source Information

From the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore.

Address reprint requests to Dr. Chaisson at Johns Hopkins Hospital, 600 N. Wolfe St., Carnegie 292, Baltimore, MD 21287-6220.

Full Text of this Article

Related Letters:

Race, Sex, Drug Use, and Human Immunodeficiency Virus Disease
Hogg R. S., Craib K., Montaner J. S.G., Schechter M. T., Turner B. J., Markson L. E., Fanning T. R., Chaisson R. E., Moore R. D.
Extract | Full Text  
N Engl J Med 1996; 334:123-124, Jan 11, 1996. Correspondence

This article has been cited by other articles:

• Silverberg, M. J., Leyden, W., Horberg, M. A., DeLorenze, G. N., Klein, D., Quesenberry, C. P. Jr (2007). Older Age and the Response to and Tolerability of Antiretroviral Therapy. Arch Intern Med 167: 684-691 [Abstract] [Full Text]  
• Cargill, V. A., Stone, V. E., Robinson, M. R. (2004). HIV Treatment in African Americans: Challenges and Opportunities. Journal of Black Psychology 30: 24-39 [Abstract]  
• Pakyz, A. L., Newberry, Y., Townsend, G. C. (2003). Human Immunodeficiency Virus Infection: A Focus on Women. Journal of Pharmacy Practice 16: 170-181 [Abstract]  
• Schackman, B. R., Freedberg, K. A., Weinstein, M. C., Sax, P. E., Losina, E., Zhang, H., Goldie, S. J. (2002). Cost-effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults. Arch Intern Med 162: 2478-2486 [Abstract] [Full Text]  
• Levine, A. M. (2002). Evaluation and Management of HIV-Infected Women. ANN INTERN MED 136: 228-242 [Abstract] [Full Text]  
• Schackman, B. R., Goldie, S. J., Weinstein, M. C., Losina, E., Zhang, H., Freedberg, K. A. (2001). Cost-Effectiveness of Earlier Initiation of Antiretroviral Therapy for Uninsured HIV-Infected Adults. Am. J. Public Health 91: 1456-1463 [Abstract] [Full Text]  
• Sterling, T. R., Vlahov, D., Astemborski, J., Hoover, D. R., Margolick, J. B., Quinn, T. C. (2001). Initial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men. NEJM 344: 720-725 [Abstract] [Full Text]  
• Schwarcz, S. K., Hsu, L. C., Vittinghoff, E., Katz, M. H. (2000). Impact of Protease Inhibitors and Other Antiretroviral Treatments on Acquired Immunodeficiency Syndrome Survival in San Francisco, California, 1987-1996. Am J Epidemiol 152: 178-185 [Abstract] [Full Text]  
• Holterman, L., Niphuis, H., Koornstra, W., Dubbes, R., ten Haaft, P., Heeney, J. L. (2000). The rate of progression to AIDS is independent of virus dose in simian immunodeficiency virus-infected macaques. J. Gen. Virol. 81: 1719-1726 [Abstract] [Full Text]  
• Whitman, S., Murphy, J., Cohen, M., Sherer, R. (2000). Marked Declines in Human Immunodeficiency Virus-Related Mortality in Chicago in Women, African Americans, Hispanics, Young Adults, and Injection Drug Users, From 1995 Through 1997. Arch Intern Med 160: 365-369 [Abstract] [Full Text]  
• Sulkowski, M. S., Thomas, D. L., Chaisson, R. E., Moore, R. D. (2000). Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection. JAMA 283: 74-80 [Abstract] [Full Text]  
• Lucas, G. M., Chaisson, R. E., Moore, R. D. (1999). Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions. ANN INTERN MED 131: 81-87 [Abstract] [Full Text]  
• Shapiro, M. F., Morton, S. C., McCaffrey, D. F., Senterfitt, J. W., Fleishman, J. A., Perlman, J. F., Athey, L. A., Keesey, J. W., Goldman, D. P., Berry, S. H., Bozzette, S. A., Additional Authors From the HCSUS Consortium, (1999). Variations in the Care of HIV-Infected Adults in the United States: Results From the HIV Cost and Services Utilization Study. JAMA 281: 2305-2315 [Abstract] [Full Text]  
• Goldie, S. J., Weinstein, M. C., Kuntz, K. M., Freedberg, K. A. (1999). The Costs, Clinical Benefits, and Cost-Effectiveness of Screening for Cervical Cancer in HIV-Infected Women. ANN INTERN MED 130: 97-107 [Abstract] [Full Text]  
• Crystal, S., Sambamoorthi, U. (1998). Health Care Needs and Services Delivery for Older Persons with HIV/AIDS: Issues and Research Challenges. Research on Aging 20: 739-759 [Abstract]  
• Sherer, R. (1998). Adherence and Antiretroviral Therapy in Injection Drug Users. JAMA 280: 567-568 [Full Text]  
• Rose, D. N. (1998). AIDS Drug Regimens That Are Worth Their Costs. JAMA 279: 160-161 [Full Text]  
• Pezzotti, P., Phillips, A. N, Dorrucci, M., Lepri, A. C., Galai, N., Vlahov, D., Rezza, G. (1996). Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. BMJ 313: 583-586 [Abstract] [Full Text]  
• Hogg, R. S., Craib, K., Montaner, J. S.G., Schechter, M. T., Turner, B. J., Markson, L. E., Fanning, T. R., Chaisson, R. E., Moore, R. D. (1996). Race, Sex, Drug Use, and Human Immunodeficiency Virus Disease. NEJM 334: 123-124 [Full Text]  
• (1995). Demographics of HIV Survival Revisited. AIDS Clin Care 1995: 3-3 [Full Text]